BioCentury | Apr 28, 2017
Politics, Policy & Law

Access and innovation in Japan

...Tokyo:4519), which is majority-owned by Roche (SIX:ROG; OTCQX:RHHBY); (C) PMDA simultaneously approved an NDA for tofogliflozin...
...SIX:ROG; OTCQX:RHHBY) Alecensa alectinib (B) Non-small cell lung cancer (NSCLC) 7/4/14 Sanofi (Euronext:SAN; NYSE:SNY) Apleway tofogliflozin...
BioCentury | Nov 23, 2015
Company News

Chugai, Kowa, Sanofi deal

...Kowa and Chugai expanded a 2012 deal to develop Chugai’s diabetes drug Deberza tofogliflozin hydrate in...
...upfront payment and is eligible to receive milestones, plus royalties. Sanofi and Kowa are co-developing Deberza...
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...combination of canagliflozin and immediate-release metformin. At least one other SGLT2 is in Phase III: tofogliflozin...
BioCentury | Nov 5, 2012
Company News

Chugai, Kowa, Sanofi deal

...Chugai granted Kowa and Sanofi rights to co-develop Chugai's diabetes compound CSG452 in Japan. The three...
...the product outside Japan. Last July, Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) returned ex-Japanese rights to CSG452...
...pipeline. At the time, Chugai said it would seek a new partner for development of CSG452...
BioCentury | Oct 30, 2012
Company News

Chugai to co-develop diabetes candidate in Japan with Kowa, Sanofi

...Kowa Co. Ltd. (Nagoya, Japan) and Sanofi (Euronext:SAN; NYSE:SNY) rights to co-develop Chugai's diabetes compound CSG452...
...responsible for submitting regulatory applications. Chugai, which will manufacture the product, is eligible for milestones. CSG452...
...Japan to treat Type II diabetes. Last July, Roche (SIX:ROG; OTCQX:RHHBY) returned ex-Japanese rights to CSG452...
BioCentury | Jul 11, 2011
Company News

Chugai, Roche deal

...Roche terminated a 2007 deal and returned ex-Japanese rights to diabetes candidate CSG452 to Chugai. Roche...
...submission planned for 2013. Chugai said it will seek a new partner for development of CSG452...
BioCentury | Jul 5, 2011
Company News

Roche returns rights to Chugai for diabetes candidate

...Roche (SIX:ROG; OTCQX:RHHBY) returned ex-Japanese rights to diabetes candidate CSG452 to Chugai Pharmaceutical Co. Ltd. (Tokyo:4519...
...submission planned for 2013. Chugai said it will seek a new partner for development of CSG452...
BioCentury | Jan 25, 2010
Product Development

SGLT2 Pipeline

...II Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) LX4211 Ph II Roche (SIX:ROG; OTCQX:RHHBY)/Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) RG7201...
BioCentury | Apr 27, 2009
Clinical News

R7201: Phase IIb started

...began a double-blind, placebo-controlled, international Phase Ilb trial to evaluate 5 dose levels of oral R7201...
...majority-owned by Roche. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG), Basel, Switzerland Product: R7201...
Items per page:
1 - 9 of 9